Aging, menopause, cardiovascular disease and HRT

  title={Aging, menopause, cardiovascular disease and HRT},
  author={The Writing Group on behalf of the Workshop Consensus},
  pages={368 - 377}
  • The Writing Group on behalf of the Workshop Consensus
  • Published 1 January 2009
  • Medicine
  • Climacteric
. Cardiovascular disease is the number-one killer of women in the Western world. . The public, and many physicians, have a very low awareness of the relevance of cardiovascular disease to menopausal women. . The public and many physicians are concerned that menopausal treatments (particularly hormonal therapies) increase the risk of cardiovascular disease, despite recent evidence showing that, in general, this is not the case in all age groups. 
9 Citations
Metabolic syndrome in older women
  • M. Shalina
  • Medicine
    Journal of obstetrics and women's diseases
  • 2019
The article highlights the role of pathogenetic, multi-component therapy, including menopausal hormone one, in the treatment of metabolic disorders in menopause and the need for early diagnosis of metabolic syndrome in older women.
Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health
This study aims to demonstrate the efforts towards in-situ applicability of EMMARM, as to provide real-time information about prolapse preoperatively and the importance of cleanliness and tubal integrity in the early stages of pregnancy.
Different tools for estimating cardiovascular risk in Brazilian postmenopausal women
By using only FRS to estimate cardiovascular risk, a substantial number of postmenopausal women showing evidence of MetS were not identified, even though women with MetS are at higher risk of CVD.
The Women's Health Initiative Estrogen-alone Trial had differential disease and medical expenditure consequences across age groups.
The decline in ET utilization had differential disease and expenditure consequences by age groups in the United States, and the lack of inclusion of vasomotor symptom benefit and costs of alternative medications for these symptoms in the analysis was limited.
The cardio-metabolic profile and bone mineral density in African and Indian postmenopausal women.
There is a high prevalence of cardiovascular risks and low BMD amongst the local menopausal population, irrespective of ethnicity, and a statistically significant correlation were observed between serum LDL-cholesterol values and BMD.
Stress at the place of work and cognitive functions among women performing intellectual work during peri- and post-menopausal period.
  • M. Gujski, J. Pinkas, I. Bojar
  • Medicine, Psychology
    International journal of occupational medicine and environmental health
  • 2017
Cognitive functions of the examined women remained within the range of average evaluations, and were correlated with stress-inducing factors at the place of work.
Medikamentöse Therapiemöglichkeiten in der Menopause
Medicinal treatment options in the menopause are primarily limited to hormonal therapy, in most cases hysterectomized women are treated only with estrogen and women with a uterus are treated with a sequential or continuous combination with progestogen.
Epidemiology of Cardiovascular disease and associated risk factors in Gaza Strip- Palestine
La situation dans the bande de Gaza est alarmante, les efforts et the recherche de strategies visant a reduire le risque cardiovasculaire sont souhaitables.


The protective effects of estrogen on the cardiovascular system.
Molecular and Cellular Basis of Cardiovascular Gender Differences
This review considers gender differences in the molecular and cellular physiology of the heart and blood vessels in health and disease, highlighting understudied areas that can help resolve the current controversy regarding hormone replacement therapy and improve cardiovascular health in women.
Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists
Both gynecologists and cardiovascular physicians have an important role to play in identifying perimenopausal women at risk of cardiovascular morbidity and mortality, and should work as a team to identify and manage risk factors, such as hypertension.
Menopause and stroke and the effects of hormonal therapy
  • R. Lobo
  • Medicine, Psychology
    Climacteric : the journal of the International Menopause Society
  • 2007
The current data suggest no increased risk of stroke with hormone therapy in younger (50–59 years) normotensive postmenopausal women, particularly when lower doses are prescribed soon after menopause, as well as several recent observational studies, which will be presented.
HRT and the young at heart.
New research supports the concept that hormone-replacement therapy has different effects on blood vessels in younger menopausal women (50 to 59 years old) than in women long after menopause, underscoring the need for greater understanding of the effects of HRT on heart disease.
Postmenopausal hormone therapy in clinical perspective
The literature indicates similar benefit of postmenopausal hormone therapy, in women who initiate hormone therapy in close proximity to menopause, to other medications used for the primary prevention of coronory heart disease in women.
Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis
There was no convincing relationship between postmenopausal status and cardiovascular disease, however, there was a modest effect of early menopause on cardiovascular disease.
Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy.
Hormone therapy is associated with an increased risk of stroke, and this increased risk does not appear to be related to the timing of the initiation of HT, in younger women, with lower stroke risk.
Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation.
Data support the possibility that timing of HT initiation in relation to menopause onset or to age might influence coronary risk, and suggest a reduced risk of coronary disease for current users of HT.